Bayer Focusing On Early CKD Testing In Kerendia US Launch

Less Than 50% Of Doctors Use UACR For Earlier Diagnosis

The company, which set a list price of $19 per day, sees awareness of diagnosing chronic kidney disease in type 2 diabetes patients as the top challenge for newly approved finerenone in the US.

Human kidneys medicine treatment concept
Kerendia (finerenone) is a kidney disease-specific treatment for CKD associated with diabetes • Source: Alamy

Bayer AG brought in a new sales team specifically to promote Kerendia (finerenone) in the US for chronic kidney disease (CKD) in patients with type 2 diabetes, and those representatives will hit the ground running later this month. The US Food and Drug Administration approved the non-steroidal mineralocorticoid receptor antagonist on 9 July and the company is working to manufacture enough of the once-daily pills to distribute the product to retail pharmacies within the next two weeks.

Kerendia is indicated to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, kidney failure, cardiovascular death, non-fatal...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from New Products

Biogen Edges Closer To Growth On Strong Q2

 

Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.

PTC To Challenge BioMarin In PKU With Oral Sephience

 
• By 

PTC plans to compete with BioMarin’s two phenylketonuria drugs with efficacy data showing strong reduction of phenylalanine and ability for patients to liberalize their diets.

Apellis’ Empaveli Expansion Underway In Rare Kidney Disease

 

The US FDA approved the complement C3 inhibitor for new indications in C3G and primary IC-MPGN, providing a new growth opportunity for Apellis.

Analysts Not Impressed With Adaptimmune’s Survival Attempts

 
• By 

The company is getting just $55m from the sale of Tecelra and a couple of late-stage T-cell therapies to US WorldMeds.

More from Scrip

Bristol’s Q2 Earnings Homerun Overshadowed By Clinical Trial Review Curveball

 
• By 

Second quarter revenue and EPS beat consensus and BMS raised its 2025 revenue guidance, but after multiple recent Phase III failures, executives said the company is reviewing studies with near-term readouts.

AbbVie Raises Full-Year Sales Guidance On Skyrizi/Rinvoq Strength

 
• By 

AbbVie now expects the two Humira successors to bring in $25bn this year. On its Q2 earnings call, the firm also pointed to strength in neuroscience, with 24% growth.

Biogen Edges Closer To Growth On Strong Q2

 

Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.